Following the panel, an interview session at the Havas Café provided a deeper dive into the implications of GLP-1 therapies. Industry leaders discussed the broader societal benefits, from improving quality of life to reducing healthcare costs. The dialogue emphasized the importance of innovation and collaboration across the healthcare ecosystem to address challenges in chronic disease management​